These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 21804539)

  • 1. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
    Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
    Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum suPAR in patients with FSGS: trash or treasure?
    Maas RJ; Deegens JK; Wetzels JF
    Pediatr Nephrol; 2013 Jul; 28(7):1041-8. PubMed ID: 23515666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
    BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
    Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
    Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
    Kronbichler A; Saleem MA; Meijers B; Shin JI
    J Immunol Res; 2016; 2016():2068691. PubMed ID: 27504461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFα pathway blockade ameliorates toxic effects of FSGS plasma on podocyte cytoskeleton and β3 integrin activation.
    Bitzan M; Babayeva S; Vasudevan A; Goodyer P; Torban E
    Pediatr Nephrol; 2012 Dec; 27(12):2217-26. PubMed ID: 22538781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. suPAR and chronic kidney disease-a podocyte story.
    Zeier M; Reiser J
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A suPAR circulating factor causes kidney disease.
    Shankland SJ; Pollak MR
    Nat Med; 2011 Aug; 17(8):926-7. PubMed ID: 21818086
    [No Abstract]   [Full Text] [Related]  

  • 17. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J; Wei C; Tumlin J
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
    Kim EY; Roshanravan H; Dryer SE
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
    Bock ME; Price HE; Gallon L; Langman CB
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.